Proinflammatory IgG Fc structures in patients with severe COVID-19.
Saborni ChakrabortyJoseph GonzalezKarlie EdwardsVamsee MallajosyulaAnthony S BuzzancoRobert SherwoodCindy BuffoneNimish KathaleSusan ProvidenzaMarkus M XieJason R AndrewsCatherine A BlishUpinder SinghHaley DuganPatrick C WilsonTho D PhamScott D BoydKari C NadeauBenjamin A PinskySheng ZhangMatthew J MemoliJeffery K TaubenbergerTasha MoralesJeffrey M SchapiroGene S TanPrasanna JagannathanTaia T WangPublished in: medRxiv : the preprint server for health sciences (2020)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections can cause Coronavirus Disease 2019 (COVID-19), which manifests with a range of severities from mild illness to life threatening pneumonia and multi-organ failure. Severe COVID-19 is characterized by an inflammatory signature including high levels of inflammatory cytokines, alveolar inflammatory infiltrates and vascular microthrombi. Here we show that severe COVID-19 patients produced a unique serologic signature, including increased IgG1 with afucosylated Fc glycans. This Fc modification on SARS-CoV-2 IgGs enhanced interactions with the activating FcγR, FcγRIIIa; when incorporated into immune complexes, Fc afucosylation enhanced production of inflammatory cytokines by monocytes, including IL-6 and TNF. These results show that disease severity in COVID-19 correlates with the presence of afucosylated IgG1, a pro-inflammatory IgG Fc modification.